コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ntravenous test (e.g., a glucose clamp or an intravenous glucose tolerance test).
2 in secretory response (AIR; assessed by 25-g intravenous glucose tolerance test).
3 (S(I)), as assessed by a frequently sampled intravenous glucose tolerance test.
4 sulin sensitivity (SI) was measured using an intravenous glucose tolerance test.
5 Insulin sensitivity as measured by an intravenous glucose tolerance test.
6 tation and animals were then subjected to an intravenous glucose tolerance test.
7 stimulation index of 4.02 in response to an intravenous glucose tolerance test.
8 sample, insulin-modified, frequently sampled intravenous glucose tolerance test.
9 SI was determined by intravenous glucose tolerance test.
10 the insulin curve in the first 10 min of the intravenous glucose tolerance test.
11 ponse and insulin sensitivity as measured by intravenous glucose tolerance test.
12 ady-state levels and continued through a 3-h intravenous glucose tolerance test.
13 vity was measured using the insulin-modified intravenous glucose tolerance test.
14 Insulin resistance was confirmed through an intravenous glucose tolerance test.
15 e (AIR) were derived from frequently sampled intravenous glucose tolerance test.
16 , acute insulin secretion was measured by an intravenous glucose tolerance test.
17 vity was assessed using a frequently sampled intravenous glucose tolerance test.
18 on (disposition index [DI]) were measured by intravenous glucose tolerance test.
19 was assessed by using the Frequently Sampled Intravenous Glucose Tolerance Test.
20 est followed by a skeletal muscle biopsy and intravenous glucose tolerance test.
21 from the insulin-modified frequently sampled intravenous glucose tolerance test.
22 sent and 41 underwent the frequently sampled intravenous glucose tolerance test.
23 directly measured using a frequently sampled intravenous glucose tolerance test.
24 d, and insulin sensitivity was determined by intravenous glucose tolerance test.
25 sample, insulin-enhanced, frequently sampled intravenous glucose tolerance test.
26 itivity was determined by frequently sampled intravenous glucose tolerance test.
27 vely, as assessed using a frequently sampled intravenous glucose tolerance test.
28 x, both obtained from the frequently sampled intravenous glucose tolerance test.
29 ty was estimated with the frequently sampled intravenous-glucose-tolerance test.
30 -sample, insulin-modified frequently sampled intravenous-glucose-tolerance test.
31 s measured by the disposition index after an intravenous-glucose-tolerance test.
32 were measured by using a frequently sampled intravenous-glucose-tolerance test.
33 with normal glucose profiles in response to intravenous glucose tolerance tests.
34 f assigned treatment using both the oral and intravenous glucose tolerance tests.
35 xpansion, and 53 controls underwent oral and intravenous glucose tolerance tests.
36 e <126 mg/dl and were phenotyped by oral and intravenous glucose tolerance tests.
37 and disposition index (DI) were assessed by intravenous glucose tolerance testing.
38 virtually identical to that obtained during intravenous glucose tolerance tests (71.6+/-6.1% of tota
39 the curve and glucose disappearance rate on intravenous glucose tolerance test, all of which worsene
40 dministration of exogenous insulin during an intravenous glucose tolerance test allows the use of the
41 ivity index (S(i)) from a frequently sampled intravenous glucose tolerance test among African-America
42 nsitivity (S(i)) from the frequently sampled intravenous glucose tolerance test among African-America
43 easured directly from the frequently sampled intravenous glucose tolerance test among black, Hispanic
44 asured insulin sensitivity index (S(I)) from intravenous glucose tolerance testing among African-Amer
45 an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test and by a dual-energy
46 sulin secretion using the frequently sampled intravenous glucose tolerance test and insulin sensitivi
47 ects were examined with a frequently sampled intravenous glucose tolerance test and meal tolerance te
48 ulin sensitivity (determined by the modified intravenous glucose tolerance test and minimal model ana
49 were determined by the tolbutamide-modified intravenous glucose tolerance test and minimal modeling,
50 veness (S(G)), which were determined from an intravenous glucose tolerance test and minimal modeling.
51 ody insulin sensitivity index (S(I)) with an intravenous glucose tolerance test and minimal modeling.
53 second phase insulin release in response to intravenous glucose tolerance test and suppressed postpr
54 x ml(-1)), estimated by a frequently sampled intravenous glucose tolerance test and the minimal model
55 vity (SI), estimated by a frequently sampled intravenous glucose tolerance test and the minimal model
57 phy, respectively; S(i) was assessed with an intravenous-glucose-tolerance test and minimal modeling.
58 were measured by using a frequently sampled intravenous-glucose-tolerance test and minimal modeling.
60 mes were changes in Si (measured by using an intravenous glucose tolerance test) and cardiovascular r
61 rinsulinemic clamp), insulin secretion (25-g intravenous glucose tolerance test), and endogenous gluc
62 abolic testing by mixed meal tolerance test, intravenous glucose tolerance test, and arginine stimula
63 (S(I)) was measured by a frequently sampled intravenous glucose tolerance test, and CRP was measured
64 BCF) were determined from frequently sampled intravenous glucose tolerance tests, and total body fat
65 [AIR]), as derived from a frequently sampled intravenous glucose tolerance test, as well as common ca
68 ixed meal and underwent a frequently sampled intravenous glucose tolerance test before and after 2 ye
73 ive insulin) had higher DRs than first-phase intravenous glucose tolerance test-derived incremental i
74 tion were assessed with a frequently sampled intravenous-glucose-tolerance test, dual-energy X-ray ab
75 tion was assessed using a frequently sampled intravenous glucose tolerance test (first-phase insulin
76 aits were measured by the frequently sampled intravenous glucose tolerance test (four cohorts) or eug
77 point was change in SI by frequently sampled intravenous glucose tolerance test from entry to week 12
78 ients were submitted to a frequently sampled intravenous glucose tolerance test (FSIGT) with the stim
79 rom the insulin-modified, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated
80 lerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conduc
83 ch subject underwent four frequently sampled intravenous glucose tolerance tests (FSIGTT), one with t
85 ex (SI) calculated from a frequently sampled intravenous glucose tolerance test (FSIVGTT) after the m
86 lowing tests: 1) frequently sampled 0.3-g/kg intravenous glucose tolerance test (FSIVGTT) with MinMod
89 nemic-euglycemic glucose clamp technique and intravenous-glucose-tolerance test have indicated that i
90 mal model analysis of the frequently sampled intravenous glucose tolerance test in 1,625 men and wome
91 ulin sensitivity (S(I)) was measured with an intravenous glucose tolerance test in obese HIV+ women r
92 tance was measured with a frequently sampled intravenous glucose tolerance test in the Insulin Resist
93 administration protocols, we performed three intravenous glucose tolerance tests in each of seven obe
97 index (SI) assessed by a frequently sampled intravenous glucose tolerance test, insulin secretion ra
99 euglycemic hyperinsulinemic clamp (EHC), by intravenous glucose tolerance test (IVGTT) and by oral g
100 condition, we assessed glucose metabolism by intravenous glucose tolerance test (IVGTT) and euglycemi
102 exes with analogous indexes obtained from an intravenous glucose tolerance test (IVGTT) and hyperglyc
104 sing clamp and minimal model analysis of the intravenous glucose tolerance test (IVGTT) to document p
106 and normalization of glucose disposal during intravenous glucose tolerance tests (IVGTT) remains crit
108 dlimb lymph insulin profile during simulated intravenous glucose tolerance tests (IVGTTs) in anesthet
110 Oral glucose tolerance tests (OGTTs) and intravenous glucose tolerance tests (IVGTTs) were perfor
113 glycemic clamps), and insulin secretion [via intravenous-glucose-tolerance tests (IVGTTs)].Fifty-four
115 ulin action (Si), measured with the meal and intravenous glucose tolerance test models, was highly co
116 ic clamp), acute insulin response (AIR, 25-g intravenous glucose tolerance test, n = 118 normal gluco
118 l antibody-negative women underwent oral and intravenous glucose tolerance tests (OGTT; IVGTT), hyper
120 y and an insulin-modified frequently sampled intravenous glucose tolerance test on the second day.
121 ed beta-cell function, we performed oral and intravenous glucose tolerance tests on mutation carriers
126 l model analysis with the frequently sampled intravenous glucose tolerance test provides an effective
128 of EXN during mixed meal tolerance test and intravenous glucose tolerance test results in improved f
131 = 389) had first-phase insulin release on an intravenous glucose tolerance test that was higher than
133 emic clamps in adults and frequently sampled intravenous glucose tolerance tests using Bergman minima
134 irst-phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 i
135 r sensor lag times (<4.2 min) in response to intravenous glucose tolerance tests versus burst NO-rele
136 changes of portal insulin (as measured by an intravenous glucose tolerance test) versus slow changes
140 ity (SI) as determined by frequently sampled intravenous glucose tolerance tests was measured over a
141 d first-phase insulin release in response to intravenous glucose tolerance testing, was observed afte
143 lucose levels, urine glucose levels, and the intravenous glucose tolerance test were used to monitor
148 abetic, non-Amish subjects (n = 48), in whom intravenous glucose tolerance tests were performed, and
149 n levels returned to normal, and K values of intravenous glucose tolerance tests were significantly h
150 insulin secretion rates during both oral and intravenous glucose tolerance tests were used to generat
151 n sensitivity (SI) by the frequently sampled intravenous glucose tolerance test with analysis by the
152 th a validated, 12-sample, insulin-enhanced, intravenous glucose tolerance test with minimal model an
153 the tolbutamide-modified, frequently sampled intravenous glucose tolerance test with minimal modeling
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。